Two drug development specialists based in the US state of California, STA Pharmaceutical, part of the WuXi AppTec group, and Regulus Therapeutics, have agreed to collaborate on oligonucleotide synthesis for research and mid-scale non-GMP/cGMP manufacturing. The pact follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.
Original Article: WuXi STA and Regulus in Oligonucleotide Synthesis Pact